期刊
CANCER AND METASTASIS REVIEWS
卷 37, 期 1, 页码 107-124出版社
SPRINGER
DOI: 10.1007/s10555-017-9717-6
关键词
RNA interference; Delivery systems; Nanoparticles; Cancer therapy
类别
资金
- National Institutes of Health through Cancer Center Support Grant [P30CA016672, CA217685, P50 CA098258, UH3 TR000943, U01 CA213759, R35 CA209904]
- Ovarian Cancer Research Fund, Inc.
- CPRIT [RP120214, DP150091]
- V-Foundation
- Frank McGraw Memorial Chair in Cancer Research
- American Cancer Society Research Professor Award
- NATIONAL CANCER INSTITUTE [R35CA209904, P50CA217685, R01CA177909, P30CA016672, U01CA213759, P50CA098258] Funding Source: NIH RePORTER
- NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UH3TR000943] Funding Source: NIH RePORTER
RNA interference (RNAi) is considered a highly specific approach for gene silencing and holds tremendous potential for treatment of various pathologic conditions such as cardiovascular diseases, viral infections, and cancer. Although gene silencing approaches such as RNAi are widely used in preclinical models, the clinical application of RNAi is challenging primarily because of the difficulty in achieving successful systemic delivery. Effective delivery systems are essential to enable the full therapeutic potential of RNAi. An ideal nanocarrier not only addresses the challenges of delivering naked siRNA/miRNA, including its chemically unstable features, extracellular and intracellular barriers, and innate immune stimulation, but also offers smart targeted delivery. Over the past decade, great efforts have been undertaken to develop RNAi delivery systems that overcome these obstacles. This review presents an update on current progress in the therapeutic application of RNAi with a focus on cancer therapy and strategies for optimizing delivery systems, such as lipid-based nanoparticles.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据